Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Nasal Spray for Awake Sedation in Breast-Conserving Surgery
NCT07350928Phase 3Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Placebo with Dexmedetomidine (2 arms). Primary endpoints: Observer's Assessment of Alertness/Sedation and Numerical Rating Scale and Hospital Anxiety and Depression Scale. Started Mar 2025; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07350928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350928.